Because the efficacy of anti-BCMA therapy has been demonstrated and there are reports that a small subgroup of less-differentiated myeloma clones expresses CD19, a combination of humanized anti-CD19 and anti-BCMA CAR T-cell infusions seemed reasonable to us. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.